BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Earnings for BioAtla, Inc. (BCAB)
Earnings in 2023 (TTM): $-123,462,000
According to BioAtla, Inc.'s latest financial reports the company's current earnings (TTM) are $-123,462,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of BioAtla, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-123,462,000 | $-123,462,000 |
| 2022 | $-106,482,000 | $-105,283,000 |
| 2021 | $-95,402,000 | $-95,406,000 |
| 2020 | $-35,853,000 | $-37,241,000 |
| 2019 | $-29,855,000 | $-31,402,000 |
| 2018 | $-28,979,000 | $-28,979,000 |